Share
Immunotherapy Integrated Research Center (IIRC)
Faculty
Alphabetical Listing:
Select a letter to display a list of Faculty members
Retrovirus-based gene transfer into hematopoietic stem cells has emerged as a viable treatment for genetic, malignant and infectious diseases with the potential to significantly decrease global disease burden.
Phone: (206) 667-7110
Fax: (206) 667-6124
Phone: (206) 667-4412
Fax: (206) 667-6936
The Bielas Laboratory studies the fundamental and clinical implications of nuclear and mitochondrial DNA mutations in the pathogenesis of cancer and age-related disease.
Phone: (206) 667-3170
Fax: (206) 667-2537
Laboratory studies are focused on preventing graft-versus-host-disease for children undergoing allogeneic stem cell transplants, the discovery of leukemia associated minor histocompatibility antigens and the development of adoptive T cell immunotherapy.
Phone: (206) 667-6572
Fax: (206) 667-7983
Infections in the immunocompromised host, especially diagnosis, prevention and treatment of CMV, VZV, BK virus, adenovirus, and respiratory virus infections. Research includes understanding the genetic basis of infection complications, genome and gene expression studies.
Phone: (206) 667-6706
Fax: (206) 667-4411
Research is centered on 1) understanding the factors associated with successful adoptive transfer of immune T cells and improving the outcomes of both native and gene-modified T cells targeting viral and tumor antigens, 2) developing methods that improve the survival, proliferation and anti-tumor activity of infused T-cell products so as to better eliminate tumor targets and 3) clinical strategies to modulate the host immune environment as a means to optimally activate T cells in humans.
Phone: (206) 667-4369
Fax: (206) 667-7983
Immunotherapy cancer vaccines and solid tumor research
Phone: (206) 667-4141
Fax: (206) 667-6366
The Clurman Lab studies how cell division is regulated in normal cells, and how abnormal control of cell division leads to cancer. They hope to use these mechanistic insights into tumor formation to develop new cancer treatment strategies.
Phone: (206) 667-4524
Fax: (206) 667-5255
Understanding the mechanisms underlying endogenous (natural) thymic regeneration so that new therapies might be developed to enhance T-cell immunity, as needed.
Phone: (206) 667-3204
Fax: (206) 667-7983
Clinical focus is diagnosis and management of benign and malignant hematologic disorders as well as solid tumors. Research includes developing immune-based approaches to prevent and treat relapse of myeloid cancers, including after allogeneic HSCT.
Phone: (206) 667-4082
Fax: (206) 667-2917
The Galloway Lab studies the mechanisms by which human papillomaviruses contribute to cancer, with an emphasis on types most likely to progress to cervical cancer. They work to understand the natural history of genital HPV infections and why only a small subset of women infected with high-risk HPVs develop cancer.
Phone: (206) 667-4500
Fax: (206) 667-5815
Dr. Ghajar directs the Laboratory for the Study of Metastatic Microenvironments (LSM2). The goal of his research program is to understand how microenvironments within distant tissues regulate dormancy and growth of disseminated tumor cells (DTCs), and whether these niches convey chemoresistance to dormant DTCs. His belief is that solving these puzzles will allow the development of therapeutic regimens that eradicate dormant DTCs before they can develop into full-blown metastases.
Phone: (206) 667-7080
Fax: (206) 667-2537
Laboratory and clinical research is focused on developing new immunotherapeutic approaches to treat and ultimately eradicate multiple myeloma and lymphoma.
Phone: (206) 667-5398
Fax: (206) 667-1874
Basic immunology and cancer immunobiology, and on the development and assessment of adoptive therapies with antigen-specific T cells targeting human malignancies and chronic infections.
Phone: (206) 667-7791
Fax: (206) 667-7983
Understanding how networks of signaling proteins are wired in different cell types and how they influence response to growth factors or cytotoxic agents using both hypothesis driven and systems-based data-driven approaches.
Phone: (206) 667-4149
Studies the cellular and molecular dynamics that underlie metastasis, i.e. the spread of cancer cells from a primary tumor to distant organs. The main focus of his lab is the tumor-immune cell interactions that variably promote or defend against metastasis, particularly in lung cancers.
Phone: (206) 667-3619
Fax: (206) 667-2917
The Hockenbery lab studies programmed cell death (apoptosis) pathways that are defective in many cancer cells; and the role of cancer-cell metabolism in apoptosis, oncogene functions, and environmental/dietary risk factors, including excess supply of nutrients. After identifying cancer-selective targets, they carry out small-molecule screens for inhibitors to identify lead compounds as anticancer agents.
Phone: (206) 667-4611
Fax: (206) 667-6519
Chap and Eve Alvord and Elias Alvord Chair in Neuro-Oncology,
UW MedicineResearch focus is the molecular basis of brain tumors and the development of new targeted treatment approaches. Mouse models of brain cancer that mimic disease behavior in patients have been developed which have led to clinical trials in glioma patients.
Phone: (206) 667-6117
Fax: (206) 667-7850
The initial focus was to study the role of inflammatory cell derived proteinases in diseases occurring within the lungs. To date, this has included novel findings for many disease processes including lung cancer, COPD/emphysema, acute lung injury, pulmonary infections, and pulmonary fibrosis. More recently, the focus has shifted to the tumor microenvironment.
Phone: (206) 667-3175
Fax: (206) 667-5255
The Kiem Lab is focused on research and clinical trials using stem cell biology and stem cell gene transfer with the goal of developing stem cell-based treatment strategies for patients with genetic or infectious stem cells. We are conducting studies using embryonic stem cells and induced pluripotent stem cells.
Phone: (206) 667-4409
Fax: (206) 667-6124
Tumor infiltrating lymphocyte therapy for melanoma, bladder and head and neck cancers
Phone: (206) 606-2274
Fax: (206) 606-1435
Improving treatments for patients with CLL, lymphoma and myeloma by increasing activity and decreasing toxicity
Phone: (206) 667-5616
Fax: (206) 667-6124
Research is focused immunotherapy, targeted therapies and the design of clinical trials for head and neck and lung cancers
Phone: (206) 606-6723
Fax: (206) 606-1435
Phone: (206) 667-7318
Fax: (206) 667-1319
Research centers on developing an HIV vaccine and investigating the complex relationship between HIV and the immune system and the influence of antiretroviral therapy.
Quantitative and substantive problems in cancer early detection
Phone: (206) 667-4612
Fax: (206) 667-7264
Patterning the vertebrate brain
Phone: (206) 667-5627
Fax: (206) 667-6522
New ways to prevent and treat skin cancers
by studying the systems that control cell division. These systems help prevent cells with damaged DNA from reproducing and, when they malfunction, can affect cells’ chances of becoming cancerous.
Phone: (206) 221-2632
Fax: (206) 221-4364
Mechanisms of tumor-induced immune tolerance by which tumors can escape anti-tumor immune responses, including natural and therapy-induced responses
Phone: (206) 667-6648
Fax: (206) 667-7983
Develops new ways to enhance the immune response against sarcomas.
Phone: (206) 667-6629
Fax: (206) 667-7983
Study T cell fate and function in healthy and inflamed tissues and following infection with HIV and manipulate these responses for therapeutic purposes
Phone: (206) 667-2216
Fax: (206) 667-2209
Research is focused on photon- and proton-based regimens to trigger an immune response to augment immunotherapies in solid tumors.
Phone: (206) 306-2814
Fax: (206) 417-0347
Studies focus on 1) understanding the roles of distinct T cell subsets in protective immunity to pathogens and tumors and on 2) the development and clinical application of adoptive T cell therapies for viral diseases and cancers, using unmodified and genetically modified antigen-specific T cells.
Phone: (206) 667-7791
Fax: (206) 667-7983
Research is computationally based and focuses on the adaptive immune system and its response to viral infection, with HIV a particular area of interest. Taking advantage of new high-throughput sequencing technology, in collaboration with experimental groups, we are isolating and sequencing millions of t-cell receptor VDJ rearrangements from different clonotypes
Phone: (206) 667-2571
Fax: (206) 667-1319
Studies the very first steps that lead to a productive immune response. These involve circulating “innate” immune cells that initially recognize problems, such as cells infected by a virus or transformed by malignant changes.
Phone: (206) 667-7753
Fax: (206) 667-7983
Stem cell engraftment in MHC-matched and mismatched transplants: development of nonmyeloablative conditioning regimens
Phone: (206) 667-4961
Fax: (206) 667-6124
Breast cancer genetics, investigational breast cancer treatments
Phone: (206) 606-6889
Fax: (206) 606-2023
Next-generation immunomodulatory synthetic materials, we are developing new approaches to therapeutically boost the body's natural ability to fight cancer
Phone: (206) 667-6677
Fax: (206) 667-7983
Crystallography, protein structure and function
Phone: (206) 667-4031
Fax: (206) 667-6877
Structural molecular immunology and vaccinology: using biophysical approaches to study proteins and interactions mediating or modulating adaptive and innate immune responses
Phone: (206) 667-5587
Fax: (206) 667-5939
Develops statistical/computational methods and software packages for different types of omic data, including array or sequencing data for germline/somatic point mutations, copy number alterations, DNA methylation, and gene expression.
Phone: (206) 667-3188
Fax: (206) 667-7004
Research interests involve mechanisms driving the differentiation of B cells following vaccination and infection, understanding how differences in the pre-immune repertoire influences immunity and vaccine Development
Immunotherapy; activated lymphocytes and cytokines; melanoma; kidney cancer
Phone: (206) 606-2044
Fax: (206) 606-6210
New immunotherapies for lymphoma, focusing on the approach of adoptive T cell therapy with autologous T lymphocytes genetically engineered to express a chimeric antigen receptor (CAR).
Phone: (206) 667-7269
Fax: (206) 667-1874
Adoptive T cell therapy for hematologic malignancies and in investigating the immunologic perturbations in hematopoietic stem cell transplantation
Phone: (206) 667-7073
Fax: (206) 667-7983
Research is focused on the the preclinical and early clinical development and characterization of novel antigen-directed immunotherapies for AML, the conduct of trials testing novel treatments and innovative care approaches for AML patients, and approaches to develop and improve diagnostic and prognostic tools in AML.
Phone: (206) 667-3599
Fax: (206) 667-6519
Clinical focus is treating patients with blood cancers such as leukemia, lymphoma, and multiple myeloma. Research is focused on cancer immunology, specifically the mechanisms and molecules that mediate graft-versus-host disease and graft-versus tumor.
Phone: (206) 667-6441
Fax: (206) 667-7983
Clinical trial design, modeling and statistical analyses of biomarkers, genetics and patient outcomes
Phone: (206) 667-3358
Fax: (206) 667-6358